The Revenue Problems of a Struggling Product Portfolio
Many life sciences companies of all sizes struggle to build solid product portfolios – a stable of drugs in various stages of development that later become major commercial successes. Challenges such as the following abound:
- Declining R&D productivity that makes it difficult to offset the revenue loss of drugs coming off patent
- Investments in fast-growing new therapeutic areas that turn out to have quite formidible competition (companies whose research was much further ahead than expected) or few promising compounds for in-licensing
- Poor decisions on acquisitions and licensing deals that squander revenue on products that don’t pan out
- Clinical trials designed in ways that don’t provide the evidence required by regulators, prescribers and payers
ZS has a comprehensive set of pipeline strategy consulting services – expertise that will help you devise strategies for disease areas to target, the best business development & licensing deals to make, product portolio decisions, development plans, and launch activities that generate demand.